Get started
Author

Yaşa Gül Mutlu

Observed names: Mutlu, Yaşa Gül, YAŞA GÜL MUTLU, Yasa Gul Mutlu, Yasa Mutlu Gulu, Yasa gul Mutlu, Yaşa G. Mutlu, Yaşa Gul Mutlu
ORCID: 0000-0003-1508-2822
Observed ORCID: 0000-0003-1508-2822
OpenAlex ID: A5035575970
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
2023 · Yasa Gul Mutlu, Sureyya Yıgıt Kaya, et al. · Frontiers in Immunology · 21
PDF
Should Core Needle Lymph Node Biopsy be a Relevant Alternative to Surgical Excisional Biopsy in Diagnostic Work Up of Lymphomas?
2023 · Yaşa Gül Mutlu, Berrin Balık Aydın, et al. · Eurasian Journal of Medicine · 15
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
2021 · Sinem Civriz Bozdağ, Güldane Cengiz Seval, et al. · Turkish Journal of Hematology · 13
First-line Usage of Daratumumab, Lenalidomide, Dexamethasone (DRd) Combination in a Case of Castleman Disease Variant of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome (CD-POEMS)
2022 · Omur Gokmen Sevindik, Yasa Gul Mutlu, et al. · HemaSphere · 9
Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience
2024 · Süreyya Yiğit Kaya, Yaşa Gül Mutlu, et al. · Leukemia Research · 4
Effectiveness of Gilteritinib Beyond Second‐Line Therapy in Relapsed/Refractory FLT3 ‐Mutated Acute Myeloid Leukemia: A Real‐World Multicenter Study of 171 Patients
2025 · Matteo Molica, Gema Miralles, et al. · American Journal of Hematology · 3
PDF
Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient
2023 · Süreyya Yiğit Kaya, Sebnem Bektas, et al. · Annals of Hematology · 3
Universal Use of Novel Oral Anticoagulant Prophylaxis in Myeloma Patients Undergoing IMiD-Based Therapy: Real-World Experience
2026 · Yasa Gul Mutlu, Ebrar Uzunabdullah, et al. · Journal of Clinical Medicine · 2
PDF
Predicting the CD34 content of mobilized peripheral blood leukapheresis products: single institution experience over 20 years
2023 · Yaşa G. Mutlu, Joan Sevcik, et al. · Cytotherapy · 2
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
2023 · Istemi Serin, Omur Gokmen Sevindik, et al. · Transfusion and Apheresis Science · 2
Comparison of Efficacy and Safety of Generic Plerixafor Vs Original Plerixafor in the Mobilization of Myeloma Patients
2022 · Omur Sevindik, Hülya Bilgen, et al. · Blood · 2
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
2022 · Omur Gokmen Sevindik, Mahmut Mergen, et al. · Annals of Hematology · 2
PDF
Real-world effectiveness of gilteritinib beyond second-line therapy in relapsed/refractory FLT3-mutated acute myeloid leukemia: A european multicenter study of 171 patients
2025 · Matteo Molica, Gema Miralles, et al. · Blood · 1
PDF
When high dose methotrexate stops working, a successful bridge to transplant with TEDDI-R in a case of secondary CNS lymphoma
2025 · Süreyya Yiğit Kaya, Elif Melek, et al. · Annals of Hematology · 1
Intravascular B‐cell lymphoma with generalized telangiectasias
2023 · Vedat Bugra Erol, Yaşa Gul Mutlu, et al. · JDDG Journal der Deutschen Dermatologischen Gesellschaft · 1
Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers
2023 · Sevil Sadri, İpek Yönal Hindilerden, et al. · The European Research Journal · 1
PDF
Prognostic Factors and Intensive Care Outcome in Post-Transplant Phase of Hematopoietic Stem Cell Transplantation
2022 · Yaşa Gül Mutlu, Berrin Balik Aydin, et al. · Indian Journal of Hematology and Blood Transfusion · 1
PDF
Persistent Polyclonal B-cell Lymphocytosis with Binucleated Lymphocytes (PPBL)
2021 · Berrin Balık Aydın, Yaşa Gül Mutlu, et al. · Turkish Journal of Hematology · 1
PDF
The Outcomes of Newly Diagnosed Multiple Myeloma Patients With Concurrent or Previous Solid Tumor History
2025 · Yaşa Gül Mutlu, Şerife Emre Ünsal, et al. · Clinical Lymphoma Myeloma & Leukemia
Myth or reality: Graft versus host disease after autologous hematopoietic cell transplantation, a multicentre experience
2025 · Süreyya Yiğit Kaya, Leylagül Kaynar, et al. · Transplant Immunology
Does the time since diagnosis affect the quality of life in patients with haematological malignancies at early and late period?
2025 · Berrin Balik, Yaşa Gül Mutlu, et al. · Journal of Medicine and Palliative Care
PDF
Assessing Average Proteinuria and Blood Pressure as Predictors of Kidney Survival in Autosomal Dominant Polycystic Kidney Disease
2025 · Yaşa Gül Mutlu, Mehmet Ası Oktan, et al. · Uludağ Üniversitesi Tıp Fakültesi Dergisi
PDF
Otozomal Dominant Polikistik Böbrek Hastalığında Böbrek Sağkalımı
2025 · Mutlu, Yaşa Gül, Oktan, Mehmet Ası, et al. · Uludağ Üniversitesi Tıp Fakültesi Dergisi
First Line Treatment in Newly Diagnosed Transplant Eligible Multiple Myeloma
2025 · YAŞA GÜL MUTLU, SENEM MARAL · Turkiye Klinikleri eBooks
Myeloid differentiation primary response 88 expression in central nervous system lymphomas
2024 · Berrin Balık, Yaşa Gül Mutlu, et al. · Journal of Current Hematology & Oncology Research
Works count: 35
Citation count: 84
H-index: 4
I10-index: 3
Year
Topic
Type